Dianthus Therapeutics, Inc. /DE/ 8-K

What Happened Dianthus Therapeutics, Inc. held its Annual Meeting of Stockholders on May 21, 2026 and filed an 8-K on May 22, 2026 reporting the results. Stockholders elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors (terms through the 2029 annual meeting), approved an advisory (non‑binding) vote on executive compensation, and ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Director elections (Class II, terms through 2029):
  • Sujay Kango: For 42,739,315; Withheld 479,199; Broker non‑votes 3,585,554.
  • Anne McGeorge: For 34,814,377; Withheld 8,404,137; Broker non‑votes 3,585,554.
  • Jonathan Violin, Ph.D.: For 42,799,946; Withheld 418,568; Broker non‑votes 3,585,554.
• Advisory vote on executive compensation: For 41,004,507; Against 1,713,043; Abstain 500,964; Broker non‑votes 3,585,554.
• Ratification of auditor (Deloitte & Touche LLP): For 46,298,319; Against 5,279; Abstain 500,471; Broker non‑votes: none reported.
• Meeting date: May 21, 2026; Form 8‑K filed May 22, 2026.

Why It Matters Board elections and auditor ratification affect governance and continuity. The re-election of the three Class II directors maintains the current board composition through 2029. The advisory approval of executive compensation indicates shareholder support for the company’s pay practices (note: advisory votes are non‑binding). Ratifying Deloitte ensures continuity of the company’s independent audit for fiscal 2026. Investors may also note the relatively high withheld votes for Anne McGeorge compared with the other nominees, which is a factual indicator of differing shareholder support on that director vote.